Overreliance on Chinese and Indian Manufacturers of Drugs: A Recipe for Public Health Disaster

Hooman Kashi and Kevin Ho

The Phenomenon

Roughly 90% of all medications dispensed in American pharmacies are generic.

- Over the last 10 years, generic drugs helped the U.S. health care system save nearly two trillion dollars
- U.S. national health spending projected to reach $6.2 trillion by 2028 from $3.6 trillion in 2018 (CMS.gov)
- Generic medications are an absolute necessity

- China and India are currently the manufacturers of generic medications
- India is a leading manufacturer of Finished Drug Products (FDP) bound to United States
- China is the world’s largest supplier of Active Pharmaceutical Ingredients (API) – the raw material for manufacturing FDPs in India.

The Recipe for Disaster

1. US Reliance on China and India
   - 13% of the US’s APIs come from China.
   - 18% of the US’s APIs come from India, but also 11% of the US total FDP comes from India, who relies heavily on China for their APIs to make it.

2. Lack of Trust with Overseas Products
   - Quality control issues for Chinese API:
     - 2008: Sudden anaphylactoid reactions observed in patients in the US who received heparin; 100 died
     - 2017: The FDA inspected a Chinese API manufacturer called Zhejiang Huahai Pharmaceuticals Co. and found that “they omitted from official test results that drug batches failed to meet US quality standards and instead recorded passing grades” (White 2019). API for angiotensin II receptor blocker products had unacceptably high level of N-Nitrosodimethylamine (NDMA), a potential carcinogen

3. Lack of Emergency/Crisis Plans
   - As of March 31, 2020, the US had 99 drug shortages. Many are a direct result of U.S. dependence on China for many critical drugs. If the US continues to face diplomatic tensions with China during a pandemic like COVID-19, the US will lose a significant amount of medicine imported from China and India.

What’s Next?

Emergency Preparedness

U.S. should implement a federal initiative to develop our own generic drugs for high demand medications.

- Then U.S. manufacturers should expand to producing our own supply of API
- California is attempting to create its own line of generic drugs
- U.S. can begin to acquire a reservoir of manufacturing capacity

This will:

1. Alleviate U.S. reliance on Indian FDPs
2. Ease the reliance on China’s exports of API

Bring our overseas manufacturers back to the US or operate in other countries that will consent to increased FDA oversight.

- Decreases the chance of impurities in FDPs
- Ensures manufacturing maintains FDA standards for quality control and quality assurance
- Could be done using tax incentives to support U.S. manufacturing

"If China shut the door on exports of medicines and their key ingredients and raw materials, U.S. hospitals and military hospitals and clinics would cease to function within months, if not days.”

- Rosemary Gibson, Senior Adviser at Hasting Center

Acknowledgements:

C. Michael White, PharmD, FCP, FCCP
University of Connecticut School of Pharmacy, Storrs, CT, USA

References:


